Standard BioTools/$LAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Ticker
$LAB
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
816
ISIN
US34385P1084
Website
LAB Metrics
BasicAdvanced
$482M
-
-$0.35
1.51
-
Price and volume
Market cap
$482M
Beta
1.51
52-week high
$2.41
52-week low
$0.92
Average daily volume
2.3M
Financial strength
Current ratio
6.117
Quick ratio
5.22
Long term debt to equity
5.543
Total debt to equity
6.936
Interest coverage (TTM)
-55.28%
Profitability
EBITDA (TTM)
-110.478
Gross margin (TTM)
55.67%
Net profit margin (TTM)
-78.24%
Operating margin (TTM)
-74.44%
Effective tax rate (TTM)
-0.22%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-11.63%
Return on equity (TTM)
-25.73%
Valuation
Price to revenue (TTM)
2.801
Price to book
1.06
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-3.837
Free cash flow yield (TTM)
-26.06%
Free cash flow per share (TTM)
-33.10%
Growth
Revenue change (TTM)
33.86%
Earnings per share change (TTM)
-65.33%
3-year revenue growth (CAGR)
10.94%
10-year revenue growth (CAGR)
3.75%
3-year earnings per share growth (CAGR)
-38.54%
10-year earnings per share growth (CAGR)
-15.43%
What the Analysts think about LAB
Analyst ratings (Buy, Hold, Sell) for Standard BioTools stock.
Bulls say / Bears say
Standard BioTools achieved a 50% year-over-year improvement in adjusted EBITDA and a 35% reduction in net loss in Q3 2024, driven by merger cost synergies and operational enhancements. (tipranks.com)
The company reported a 77% increase in revenue in Q3 2024 compared to the same quarter in 2023, indicating strong growth momentum. (simplywall.st)
Standard BioTools has operationalized approximately $10 million in cost reductions during Q1 2025, contributing to a 22% reduction in non-GAAP operating expenses and a 29% improvement in adjusted EBITDA year-over-year. (investing.com)
Standard BioTools reported a 10% year-over-year decline in revenue for Q1 2025, continuing the downward trend seen in Q4 2024. (investing.com)
Analysts have revised their revenue forecasts downward for Standard BioTools, now expecting a 3% decline in 2025 compared to the previous year. (simplywall.st)
The Bank of New York Mellon Corp reduced its stock position in Standard BioTools, indicating potential concerns about the company's future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
LAB Financial Performance
Revenues and expenses
LAB Earnings Performance
Company profitability
LAB News
AllArticlesVideos
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
GlobeNewsWire·5 days ago
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
GlobeNewsWire·4 weeks ago
Standard BioTools Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Standard BioTools stock?
Standard BioTools (LAB) has a market cap of $482M as of June 28, 2025.
What is the P/E ratio for Standard BioTools stock?
The price to earnings (P/E) ratio for Standard BioTools (LAB) stock is 0 as of June 28, 2025.
Does Standard BioTools stock pay dividends?
No, Standard BioTools (LAB) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Standard BioTools dividend payment date?
Standard BioTools (LAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Standard BioTools?
Standard BioTools (LAB) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.